

1 **Adverse events following immunization during COVID-19 mass**
2 **vaccination campaigns in the Democratic Republic of Congo:**
3 **Findings from active safety surveillance**

4 Kizito Kayumba^{1*}, Alemayehu Duga¹, Mosoka Papa Fallah¹, Claire Tshidibi², Nicky Lubaki²,
5 Barnabas Coulibaly¹, Benjamin Djoudalbaye¹, Efire Nora Sylvana¹, Elizabeth Gonesse¹, Senga
6 Lucy Sembuche¹, Tedi Tilahun¹, Murtala Jibril¹, Carlos Kilowe¹, Aminu Kuba¹, Antoine Mafwila
7 Lusala¹, Nebiyu Dereje¹, Nicaise Ndembi¹, Tajudeen Raji¹, Ngashi Ngongo¹

8
9 **Affiliations**

10 ¹Africa Centres for Disease Control and Prevention (Africa CDC), Addis Ababa, Ethiopia

11 ²Ministry of Health, Kinshasa, Democratic Republic of Congo

12
13 *** Corresponding author**

14 E-mail: KizitoK@afriacdc.org (KK)

15
16 **Contributorship**

17 "KK and AD are Joint First Authors"

18

19

20

21 **Abstract**

22 **Introduction:** Post-marketing safety surveillance is indispensable for ensuring safety and public
23 trust in vaccines, particularly in African settings where evidence of COVID-19 vaccine safety is
24 less documented. We aimed to identify the types of adverse events following immunization
25 (AEFIs), the overall incidence, and factors associated with AEFIs during mass vaccination
26 campaigns in The Democratic Republic of Congo (DRC).

27 **Methods:** From December 1 to 29, 2023, a prospective safety surveillance study was conducted
28 on 4,766 individuals in Kinshasa Province in DRC. They were surveyed through phone calls from
29 day 1 to 28 following the administration of the COVID-19 vaccine. We calculated AEFI incidence
30 rates by type of vaccine, sex, and age group. We identified factors associated with AEFIs using
31 multivariable logistic regression models, which were expressed by adjusted odds ratio (aOR) and
32 its 95% confidence interval (CI).

33 **Results:** A total of 4766 participants were included in the study. The median age of the
34 participants was 36 years, with an interquartile range of 27 to 48 years and 2503 (53%) were
35 females. Most of the participants (94.6%) received the Johnson & Johnson (J&J) vaccine, while
36 256 (5.4%) received the Pfizer vaccine. Nearly a quarter of participants (23.75%, 95% CI: 22.54%-
37 24.99%) reported AEFIs. The most common AEFIs reported were fever (9.61%, 95%CI: 8.88%-
38 10.48%), injection site pain (9.00%, 95%CI: 8.20%-9.85%), headache (4.11%, 95%CI: 3.57%-
39 4.72%), stiffness (1.51%, 95%CI: 1.18%-1.89 %) and myalgia (1.15%, 95%CI: 0.87%-1.49%). The
40 incidence of AEFIs was higher for the Pfizer vaccine at 34.48% (95% CI: 28.57%-40.54%) compared

41 to 23.15% (95% CI: 21.92%-24.41%) for the J&J vaccine. Participants aged 36 years and above
42 were associated with increased odds of reporting any adverse event (aOR=1.17, 95%CI: 1.02-
43 1.33), injection site pain (aOR=1.36, 95% CI: 1.11-1.66), and two or more signs (aOR=1.46, 95%CI:
44 1.10-1.94), compared to those below 36 years of age.

45 **Conclusions:** AEFI reported by about a quarter of participants and its association with vaccine
46 type and older age underscores the need for systematic vaccine safety monitoring in the
47 population. This is critical for developing future vaccination strategies tailored to individuals
48 more susceptible to AEFIs.

49 **Keywords:** COVID-19 vaccines, Safety surveillance, Pharmacovigilance, Adverse Event
50 Following Immunization, The Democratic Republic of Congo, Africa CDC, Mass Vaccination
51 Campaign.

52

53

54 **Introduction**

55 Vaccines approved for use in national immunization programmes (NIPs) are considered safe and
56 efficacious based on verifiable evidence from randomized controlled clinical trials (RCTs)¹. These
57 trials provide robust evidence supporting their safety and effectiveness. However, despite the
58 rigorous evaluation during clinical development, it is important to note that rare side effects may
59 not be detected in the early phases of clinical trials. Post-marketing safety surveillance after
60 introducing the COVID-19 vaccine into public immunization programs must identify rare and

61 previously undocumented adverse events (AEs) to address this. For instance, the non-replicating
62 vector COVID-19 vaccines such as AstraZeneca and Johnson & Johnson have been associated with
63 central venous sinus and other large vessel thrombosis (~4 per million vaccinations) and
64 thrombocytopenia.² Similarly, messenger RNA COVID-19 vaccines have also observed rare side
65 effects, such as Pfizer-BioNTech. These include anaphylaxis and myocarditis.³ Moreover, the
66 African population was not adequately represented in RTCs. Therefore, the safety of the vaccines
67 can only be determined by post-market safety surveillance.

68 Given that vaccines are often recommended for healthy individuals, the key to the success of
69 NIPs is public trust in vaccine safety.⁴ Thus, systematic vaccine safety surveillance is
70 indispensable for ensuring the safety and public trust in vaccines. Safety surveillance is expected
71 to provide additional information on incidence, distribution, and risk factors for expected and
72 unexpected serious and minor AEFIs.⁵ According to the World Health Organization (WHO), all
73 adverse events(AEs) that concern the caregiver and have associated costs and effects should be
74 reported regardless of severity.⁶ The present study aimed to investigate the occurrence of AEFI
75 during COVID-19 mass vaccination campaigns in the Democratic Republic of Congo. By
76 conducting a thorough analysis of AEFI data collected from these campaigns, this study sought to
77 provide valuable insights into the safety profile of vaccines administered. It contributed to the
78 evidence base for future vaccination efforts.

79

80

81

82 **Methods**

83 **Study Setting and Design**

84 We conducted a prospective follow-up study using an active safety surveillance approach among
85 COVID-19 vaccine recipients in the Democratic Republic of Congo (DRC). As of June 2023, 17.05
86 million individuals in the DRC have received at least one dose of COVID-19 vaccine.⁷ The Ministry
87 of Public Health of the DRC, through the Expanded Programme on Immunization (EPI), with the
88 support of Africa Centres for Disease Control and Prevention (Africa CDC) and implementing
89 partners, conducted a two-week Rapid Results Initiative (RRI) COVID-19 mass vaccination
90 campaign. From December 1 to 29, 2023 in Kinshasa province, selected vaccine recipients were
91 recruited for the follow-up. The campaign's primary objective was to accelerate the COVID-19
92 vaccination efforts and improve the low vaccination coverage in DRC. Africa CDC and EPI
93 conducted COVID-19 vaccine safety surveillance to document AEFI during the campaign.

94 During this mass vaccination campaign in the DRC, two types of COVID-19 vaccines were
95 administered: the Pfizer-BioNTech mRNA vaccine and the Johnson & Johnson (J&J) non-
96 replicating vector vaccine. The Pfizer-BioNTech vaccine utilizes mRNA technology to train the
97 immune system to recognize the spike protein of the coronavirus.⁸ On the other hand, the J&J
98 vaccine delivers the virus' DNA to host cells using an adenovirus as a delivery vehicle).⁹

99 **Study participants**

100 The COVID-19 mass vaccination campaign occurred in 159 vaccination sites distributed in 29
101 health zones of Kinshasa Province. In each vaccination site, 5% of the people vaccinated were

102 randomly selected for safety surveillance, according to the WHO recommendation⁵. Those
103 participants who received COVID-19 vaccines during the campaign consented to participate in
104 the study and provided a reachable phone number.

105 **Data Collection and Management**

106 We used a structured questionnaire adapted from the WHO safety surveillance tool⁵. The tool
107 captured data on population characteristics such as patient ID, province, profession, sex, and age,
108 as well as vaccine-related information such as batch number, number of doses, type of vaccine,
109 vaccination date, and the record of AEFI. The data concerning AEFI included the date of the caller,
110 the date of onset of the event and the type of AEFI. Follow-up calls were made on days 1, 3, 5, 7,
111 14, 21, and 28 after vaccine administration and data collection forms were used to record
112 information. The AEFI was considered serious in case of an event that results in death,
113 hospitalization, or prolongation of an existing hospitalization, persistent or significant disability
114 or incapacity, congenital anomaly/birth defect, or is life-threatening or is a medically important
115 event or reaction.⁵ Africa CDC recruited and trained a local team of AEFI focal points to conduct
116 follow-up calls to identify and monitor the AEFI. A data collection line listing form with built-in
117 validation rules was used to ensure data quality during data entry.

118

119 **Data Analysis**

120 The study's primary outcome was the experience of at least one AEFI among those receiving at
121 least one dose of any COVID-19 vaccine used during the vaccination mass campaign. Eight

122 Adverse Events for Special Interest (AESI) conditions pre-defined for surveillance based on WHO
123 recommendation, including fever, vomiting, headache, muscle pain, joint pain, body aches,
124 persistent pain at the injection site, diarrhea, and chills, were followed and monitored. We
125 dichotomized the number of events as 2 or more coded as one (1) and 0–1 coded as zero (0) for
126 our logistic regression model for the number of AEs¹⁴. The independent variables considered in
127 this analysis included age (dichotomized as <36 years and ≥36 years), sex, type of COVID-19
128 vaccines, and the number of COVID-19 vaccine doses received.

129 Descriptive statistics were used to summarize socio-demographic characteristics and vaccine-
130 related information by frequency and proportion for categorical variables and median with
131 interquartile range (IQR) for numerical variables. The cumulative incidence rate of AEFI was
132 provided by proportion along with its respective 95% confidence interval. The multivariate
133 regression models for statistical analysis using the backward-elimination regression approach
134 included all the above-mentioned independent variables. Multicollinearity was assessed by the
135 variance inflation factor (VIF) and the tolerance test (≥ 0.1). The VIF below ten was considered
136 acceptable to declare lack or absence of multicollinearity. Variables with collinearity were
137 omitted from the models. The goodness of model was assessed by the Hosmer Lemeshow
138 goodness of fit test (P-value >0.05). Multivariable logistic regression models identified factors
139 associated with experiencing AEFI and expressed by adjusted odds ratio (aOR) and its 95% CI. A
140 p-value < 0.05, together with 95%CI, was used to declare statistical significance. Stata IC version
141 16 (Stata Corp) was used to analyze the data in this study.

142

143 **Ethical considerations**

144 After the vaccine was administered, selected participants were informed about the purpose of
145 this surveillance and were asked to willingly participate in this survey. The consent was obtained
146 verbally. The verbal consent was documented on vaccine recipients' follow up form and
147 witnessed by the enumerator. Those who consented provided their phone numbers to enable
148 follow-up calls. The parents' phone numbers were provided for the vaccine recipients under 18.
149 To ensure confidentiality, de-identified data was shared with Africa CDC to analyze the vaccine's
150 safety profile following immunization. Ethical Approval was obtained from the appropriate
151 Institutional Review Board to conduct this survey and publish the findings from this analysis.

152 **Results**

153 **Population and Vaccine Characteristics**

154 The analysis included 4766 participants, with a median age of 36 (Interquartile Range [IQR]: 27-
155 48). More than half (53%) of the participants were females, and more than 70% of respondents
156 were in the 20—to 49-year age range.

157 Most participants (94.4%) received the Johnson & Johnson vaccine, and the remaining 5.6% were
158 vaccinated with the Pfizer vaccine. Those taking their second dose were 0.6%, and 99.4% took
159 their first dose (Table 1).

160

161

162 **Table 1: Population and vaccine characteristics**

Variables (N= 4766)	Group	N	% (95%CI)
Sex	Male	2,263	47.48 % (46.06%-48.91%)
	Female	2,503	52.51% (51.09-53.94%)
Type of Vaccine	J&J	4,509	94.61% (93.93%-95.23%)
	Pfizer	256	5.37% (4.75%-6.05%)
Number of doses	First	4,739	99.43% (99.18%-99.63%)
	Second	27	0.57% (0.37%-0.82%)
Age Groups	<12 years	2	0.04% (0.01-0.15%)
	12-17 years	38	0.78% (0.56%-1.09%)
	18-19 years	171	3.58% (3.08%-4.16%)
	20-29 years	1,343	28.18% (26.90%-29.47%)
	30-39 years	1,236	25.93% (24.69%-27.20%)
	40-49 years	882	18.51% (17.41%-19.63%)
	50-59 years	626	13.13% (12.19%-14.12%)
	60+ years	467	9.79% (8.97%-10.68%)
Seriousness of AEFIs	Serious	6	0.13% (0.05%-0.27%)
	Non-serious	4760	99.87% (97.73%-99.95%)

163

164

165 **Incidence and Forms of AEFI Reported**

166 Overall, 1131 (23.75%, 95% CI: 22.55% - 24.99%) reported having developed at least one AEFI
167 during the study period. The most frequent forms of AEFI reported (ranging between 1% to 10%)
168 are fever 458(9.61%, 95%CI: 8.88%-10.48%) followed by pain on injection site 429 (9.00%, 95%CI:
169 8.20%-9.85%), headache 196 (4.11%, 95%CI: 3.57%-4.72%), stiffness 72 (1.51%, 95%CI: 1.18%-
170 1.89%) and myalgia 55(1.15%, 95%CI: 0.87%-1.49%). The less frequent forms (ranging between
171 0.1% to 1%) include vomiting 24 (0.50%, 95%CI: 0.32%-0.75%), arthralgia 18(0.38%, 95%CI:
172 0.22%-0.59%), diarrhea 12(0.25%, 0.13%-0.44%), vertigo 12(0.25%.95%CI: 0.13%-0.44%) and
173 chills 10 (0.21%, 95%CI: 0.10%-0.38%). The unusual AEFIs reported (ranging between 0.01% to
174 0.1%) are heaviness of arm 4 (0.08%, 95%CI: 0.02%-0.21%), gastritis 2 (0.04%, 95%CI: 0.010%-
175 15%), blood pressure 1(0.02%, 95%CI: 0.01%-0.11%)), blurred vision 1 (0.02%, 95%CI: 0.01%-
176 0.11%), burning sensation 1 (0.02%, 95%CI: 0.01%-0.11%) (Figure1)

177 **Figure 1: Frequency of reported AEFIs**

178 **Factors Associated with the Incidence of AEFIs**

179 In the multivariable analysis, the occurrence of an AEFI was statistically associated with age and
180 the type of vaccine administered. Incidence of AEFI was higher among Pfizer vaccine recipients
181 (34.38%, 95% CI: 28.57%-40.54%) versus J&J vaccine recipients (23.15%, 95% CI: 21.92%-
182 24.41%); slightly higher among vaccine recipients aged 36 years and more (25.11%, 95%CI:
183 23.39%-26.88%) versus those below 36 years of age (22.34%, 95% CI: 20.66%-24.08%). The odds
184 of any AEs were about two times higher in the Pfizer vaccine (aOR, 1.73; 95% CI: 1.31-2.28);
185 p<0.001) as compared to J & J vaccine recipients and 17% higher among the older age group

186 (aOR, 1.17, 95%CI: 1.02-1.33; p<0.022) at 36 years and more vs. <36 years. No statistical
 187 association was found for gender and number of doses (**Table 2**).

188 **Table 2: Factors associated with the incidence of AEFIs**

Independent Variables	Group	AEFI (-)	AEFI (+)	% AEFI	aOR (95%CI)	P-value
Gender	Male	1,908	595	23.77%	1.00 (0.87-1,14)	0.986
	Female	1,726	537	23.70%	1 (Ref)	
Age	36 Years and +	1,819	610	25.11%	1.17 (1.02-1.34)	0.022*
	<36 years	1,815	522	22.34%	1 (Ref)	
Type of Vaccine	Pfizer	168	88	34.38%	1.73 (1.32-2.28)	0.001*
	Johnson & Johnson	3,466	1,044	23.15%	1 (Ref)	
Number of doses administered	1 st dose	3,613	1,126	23.76%	1.87(0.73-4.79)	0.190
	2 nd dose	21	6	22.22%	1 (Ref)	

189 * Significant factors, p<0.05

190 Fever was higher for Pfizer vaccine recipients (12.50%, 95%CI; 8.71%-17.18%) than J&J vaccine
 191 recipients (9.45%, 95%CI: 4.35%-10.34%). Recipients of the Pfizer vaccine were more likely
 192 susceptible to developing fever than recipients of the J&J vaccine (aOR=1.47, 95%CI: 1,02-2.16;
 193 p<0.048) (**Table 3**).

194

195

196 **Table 3: Factors Associated with Fever**

Independent Variables	Group	Fever(-)	Fever (+)	% Fever	aOR (95%CI)	P-value
Gender	Male	2,255	248	9.91%	1.07 (0.89-1.30)	0.452
	Female	2,053	210	9.28%	1 (Ref)	
Age	36 years and +	2,196	233	9.59%	0.96(0.82-1.20)	0.963
	<36 years	2,112	225	9.63%	1 (Ref)	
Type of Vaccine	Pfizer	224	32	12.5%	1.47(1,002-2.16)	0.048*
	Johnson & Johnson	4,084	426	9.45%	1 (Ref)	

197 * Significant factors, p<0.05

198 The proportion of persistent pain at the injection site was higher for Pfizer vaccine recipients
 199 (15.23%, 95%CI: 11.06%-20.23%) vs J&J vaccine recipients (8.65%, 95%CI: 4.29%-9.51%).
 200 Respondents vaccinated with the Pfizer Vaccine had a 76% increased risk of reporting pain at the
 201 injection site than those vaccinated with the J&J vaccine (aOR=1.76,95%CI: 1.21-5.56; p<0.003).
 202 Respondents aged 36 years and older also had a 36% increased risk of reporting pain at the site
 203 of injection compared to those aged below 36 years (aOR=1.36, 95%CI: 1.11-1.66; p<0.003).
 204 Although not statistically significant, the incidence of persistent pain at the injection site was
 205 higher after the 2nd dose (18.52%, 95%CI 6.30%-38.08%) than the first dose (8.95%, 95%CI: 8.15-
 206 %-9.79%) (Table 4)

207

208 **Table 4: Factors associated with persistent pain at the injection site**

Independent Variables	Groups	Pain (-)	Pain (+)	% Injection site pain	aOR (95%CI)	P-Value
Gender	Male	2,280	223	8.91%	0.97(0.79-1.18)	0.756
	Female	2,057	206	9.10%	1 (Ref)	
Age group	36 Years and +	2,181	248	10.21%	1.36(1.11-1.66)	0.003*
	<36 years	2,156	181	7.74%	1 (Ref)	
Type of Vaccine	Pfizer	217	39	15.23%	1.76(1.21-5.56)	0.003*
	Johnson & Johnson	4,120	390	8.65%	1 (Ref)	
Number of doses administered	1 st dose	4,315	424	8.95%	0.75(0.27-2.12)	0.598
	2 nd dose	22	5	18.52%	1 (Ref)	

209 * Significant factors, $p < 0.05$

210 Headache was more reported among Pfizer vaccine recipients (9.77%, 95%CI: 6.42%-14.07) than
 211 J&J vaccine recipients (3.79%, 95%CI: 3.25%-4.39%), muscle pain was reported by 3.52% (95%CI:
 212 1.62%-6.57%) of Pfizer vaccine recipients vs 1.02% (95%CI; 0.75%-1.35) of J&J vaccine recipients.
 213 The more significant proportion of Pfizer vaccine recipients reported two or more symptoms
 214 (10.94%, 95%CI: 7.39%-15.41%) than J&J vaccine recipients (4.06%, 95%CI: 3.50%-4.65%).
 215 Respondents aged 36 years and more had a 46% increased risk of complaining of 2 side effects
 216 or more compared to those aged below 36 years (aOR=1.46, 95%CI: 1.10-1.94; $p < 0.008$).

217 While all AEs were more predominant in Pfizer than in J&J vaccine, the odds were particularly
 218 higher for headache (aOR=2.8, 95%CI: 1.80-4.42; p<0.001) (Table 5), myalgia (aOR=3.79, 95%CI:
 219 1.83-7.84; p<0.001) (Table 6) and reporting two signs or more (aOR=3.02, 95%CI: 1.97-4.63;
 220 p<0.001). (Table 7)

221 **Table 5: Factors associated with headache**

Independent Variables	Groups	Headache (-)	Headache (+)	% Headache	OR (95%CI)	P-Value
Gender	Male	2,398	105	4.19%	1.05 (0.79-1.40)	0.707
	Female	2,172	91	4.02%	1 (Ref)	
Age	36 Years and +	2,329	100	4.12%	1.00 (0.75-1.34)	0.970
	<36 years	2,241	96	4.11%	1 (Ref)	
Type of Vaccine	Pfizer	231	25	9.77%	2.82 (1.80-4.42)	0.001*
	Johnson & Johnson	4,339	171	3.79%	1 (Ref)	
Number of doses administered	1 st dose	4,544	190	4.11%	2.85(0.37-21.93)	0.313
	2 nd dose	21	6	3.70%	1 (Ref)	

222 * Significant factors, p<0.05

223

224

225

226 **Table 6: Factors associated with muscle pain**

Independent Variables	Groups	Myalgia (-)	Myalgia (+)	% Myalgia	aOR(95%CI)	P-Value
Gender	Male	2,474	29	1.16%	1.01(0.59-1.73)	0.96
	Female	2,237	26	1.15%	1 (Ref)	
Age	36 years and +	2,398	31	1.28%	1.25(0.74-2.15)	0.401
	<36 years	2,313	24	1.03%	1 (Ref)	
Type of Vaccine	Pfizer	247	9	3.52%	3.79(1.83-7.84)	0.001*
	J& J	4,464	46	1.02%	1 (Ref)	
Number of doses administered	1 st dose	4,684	55	1.16%	Omitted	
	2 nd dose	27	0	0.00%		

227 * Significant factors, p<0.05

228 **Table 7: Factors associated with the number of signs reported by an individual**

Independent Variables	Groups	< 2 signs	2 signs and +	% 2 signs and +	aOR(95%CI)	P-value
Gender	Female	2,163	100	4.43%	0.99 (0.76-1.32)	0.992
	Male	2,392	111	4.42%	1 (Ref)	
Age	36 Years and +	2,303	126	5.19%	1.46 (1.10-1.94)	0.008*
	<36 years	2,252	85	3.64%	1 (Ref)	

	Pfizer	228	28	10.94%	3.02 (1.97-4.63)	0.001*
Type of Vaccine	Johnson & Johnson	4,327	183	4.06%	1 (Ref)	
Number of doses administered	1 st dose	4,529	211	4.43%	3.37 (0.44-25.83)	0.242
	2 nd dose	26	1	3.57%	1 (Ref)	

229 * Significant factors, p<0.05

230 Discussion

231 The clinical trials during the development of COVID-19 vaccines were mainly conducted in
 232 developed nations, so they might not optimally represent the safety situation in the African
 233 setting. The findings from our safety surveillance analysis indicate that a significant proportion of
 234 COVID-19 vaccine recipients experienced AEFIs. Specifically, the study revealed that about a
 235 quarter of individuals who received the vaccine reported any AEFIs and the AEFIs were related to
 236 the type of vaccines administered and the age of the recipients. This finding is consistent with
 237 clinical trials. In the results from the clinical trial on the safety of mRNA vaccines, more mRNA
 238 recipients than placebo recipients reported any adverse event (27% and 12%, respectively) or a
 239 related adverse event (21% and 5%).¹¹ There was a slight difference between the first and second
 240 dose, with 23.76% (95%CI: 22.55%-24.99%) experiencing AEFIs after receiving the first dose and
 241 22.22% (95%CI: 8.62%-42.26%) after the second. Furthermore, it was observed that a higher
 242 proportion of individuals who received the Pfizer vaccine (34.38%, 95% CI: 28.57%-40.54%)
 243 reported AEFIs compared to those who received the J&J vaccine (23.15%, 95% CI: 21.92%-
 244 24.41%).

245 Considerable differences were observed in the trends of AEFIs compared with results from the
246 participant-reporting studies. The UK app study showed that 71.9% (dose 1) and 68.2% (dose 2)
247 reported local side effects.¹² In the US online cohort study, AEs were reported to be 64.9%
248 partially vaccinated and 80.3% fully vaccinated with the mRNA vaccine.¹³ The proportion of AEs
249 was generally lower in our study. We can speculate that the difference might be due to potential
250 age differences in the study cohort. In our study, the population mainly comprised of younger
251 individuals (median age of 36 years) compared with the studies mentioned above (54 years; UK
252 study; 59–64 years; US study), contrasting trends of AEFIs and association of age was observed,
253 unlike other studies. Moreover, we did not assess whether participants were pre-medicated
254 before vaccination. A study conducted in Ghana revealed that almost half of the respondents
255 pre-medicated with paracetamol before vaccination.¹⁴ The importance of this factor cannot be
256 ruled out since it may contribute significantly to how an individual's immune system responds to
257 the vaccine. This creates an avenue for further research to determine if this is the case. Another
258 explanation might be that for participant-reporting studies, the vaccinees without AEs might be
259 less motivated to proactively report Zero AEFI, leading to more reports from those who
260 experienced AEs.

261 **Forms of AEFI**

262 Findings from this study showed that the most common adverse event experienced among the
263 majority after COVID-19 vaccination included fever (458 cases), pain on injection site (429 cases),
264 headache (196 cases), stiffness (72 cases), and myalgia (55 cases). The adverse events
265 experienced were no different from those experienced across the world.¹⁵ In the Ethiopian study

266 conducted by Jerso et *al.* on healthcare workers vaccinated against COVID-19¹⁶, the most
267 prevalent symptoms experienced in descending order include - pain at the injection site (64.1%),
268 fatigue (35.7%), headache (28.9%), joint pain (26.5%) and muscle pain (21.5%). In the study
269 conducted in Ghana, the prevalence of pain at the injection site also hovered around a similar
270 figure of 65.8%, which was also the most common symptom experienced post-COVID-19
271 vaccination. The second most common symptom was headache (57.5%), followed by the
272 following—tiredness (55.8%), fever (51.7%), chills (39.6%), and muscle pains (38.3%).¹⁴ In our
273 study, pain at the injection site was the second most common symptom after fever. It is,
274 however, difficult to compare those studies to ours because J&J and Pfizer were not the
275 predominant vaccines administered in those studies. However, the running theme seems to be
276 that pain at the injection site was among the first 2 most common adverse events or side effects
277 in all studies mentioned.

278 Although not statistically significant, the occurrence of injection site pain in our study was higher
279 among vaccine recipients of the second dose than those with the first dose (18.5% vs 8.9%). These
280 results corroborate the findings of the clinical trials that revealed that the proportion of almost
281 all AEFIs was higher in recipients of the second dose.^{17,18} Similar to previous studies, injection site
282 pain and muscle pain were among the most predominant AEs.^{19,20}

283

284

285

286 **Seriousness of AEFIs**

287 In our findings, 6 (0.13%) serious AEs were reported. In the clinical trial on the safety of mRNA
288 vaccines, the incidence of serious adverse events was similar in the vaccine and placebo groups
289 (0.6% and 0.5%, respectively).¹⁷

290 **Factors Associated with AEFIs**

291 Our findings revealed that the vaccine type was the most significant factor that may impact AEs.
292 Pfizer vaccine recipients were significantly associated with greater odds of reporting fever
293 (aOR=1.47, 95%CI: 1.02-2.16; p<0.048), headache (aOR=2.8, 95%CI: 1.80-4.42; p<0.001),
294 injection site pain (aOR=1.76,95%CI:1.21-5.56; p<0.003)), and having more than 2 signs
295 (aOR=3.02, 95%CI: 1.97-4.63; p<0.001), compared to the J&J vaccine recipients. Particularly,
296 Pfizer (an mRNA vaccine) was significantly associated with higher odds of AEs than J&J. These
297 results were consistent with the findings of clinical trials^{17,18} survey-based studies^{13,21,22} and a
298 government-sponsored surveillance study²³.

299 Of the baseline characteristics, female gender was not one of the evident factors associated with
300 AEFIs in this study. This was considerably different from previous findings, which showed that
301 the overall incidence of AEs in women was generally higher than that in men.^{13,21} A notable
302 finding from these studies was that female participants reported menstrual disorders and
303 unexpected vaginal bleeding after mRNA vaccination. Menstrual disorders and unexpected
304 vaginal bleeding should be carefully monitored in future surveys.

305

306 **Limitations**

307 Our results should be interpreted with caution given the following limitations. First, there might
308 be potential misclassification of outcomes, as AEFIs reported by the participants were not
309 medically reviewed and classification of the AEFI has not been conducted. Secondly, our survey
310 focused only on specific AEFIs using a pre-identified list, limiting the scope and potentially
311 excluding other AEFIs. Thirdly, as we only examined the short-term safety of COVID-19 vaccines,
312 further studies are required to evaluate the long-term AEs. Lastly, this survey did not assess for
313 any pre-existing medical conditions or whether participants were pre-medicated before
314 vaccination.

315 **Conclusion**

316 In conclusion, this survey conducted in Kinshasa (DRC) revealed that approximately 24% of
317 COVID-19 vaccine recipients aged 5–90 years reported AEFIs, and most of AEFIs were mild and
318 transient. Fever, Injection site pain, headache, and muscle pain were the most predominant AEFIs
319 reported by COVID-19 vaccine recipients. We also found that vaccination with the Pfizer vaccine
320 and age of 36 years or more were associated with the incidence of AEFIs. The Pfizer vaccine was
321 significantly associated with greater odds of reporting fever, headache, muscle pain, injection
322 site pain, and more than 2 signs compared to the J&J vaccine. Individuals aged 36 years or more
323 were associated with greater odds of reporting pain at injection site and having more than 2
324 AEFIs. Further safety surveys monitoring all potential factors are needed to generate more
325 evidence on COVID-19 vaccine safety in an African population. This information will support
326 establishing future vaccination strategies tailored to individuals potentially susceptible to AEFIs.

327 **Acknowledgments**

328 We thank the participants in this study for their great contribution to safety surveillance and the
329 Ministry of Health for sharing data with Africa CDC to enable this analysis.

330 **References**

- 331 1. WHO. Protocol template to be used as template for observational study protocols: cohort
332 event monitoring (CEM) for safety signal detection after vaccination with COVID-19
333 vaccines [Internet]. 2021 [cited 2024 Jan 8]. Available from:
334 <https://www.who.int/publications/i/item/9789240027398>
- 335 2. Islam A, Bashir MS, Joyce K, Rashid H, Laher I, Elshazly S. An Update on COVID-19 Vaccine
336 Induced Thrombotic Thrombocytopenia Syndrome and Some Management
337 Recommendations. *Molecules* [Internet]. 2021 Aug 2 [cited 2024 Jan 8];26(16). Available
338 from: [/pmc/articles/PMC8400504/](https://pubmed.ncbi.nlm.nih.gov/3400504/)
- 339 3. Centers for Disease Control and Prevention. Myocarditis and Pericarditis After mRNA
340 COVID-19 Vaccination | CDC [Internet]. Centers for Disease Control and Prevention. 2021
341 [cited 2024 Jan 8]. Available from: [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html)
342 [ncov/vaccines/safety/myocarditis.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html)
- 343 4. World Health Organization. Vaccine Safety Basics | OpenWHO [Internet]. [cited 2024 Jan
344 8]. Available from: <https://openwho.org/courses/vaccine-safety-basics>
- 345 5. World Health Organization. Safety Surveillance Manual Safety Surveillance. Available
346 from: *Safety Surveillance Manual Safety Surveillance*.


- 347 6. WHO. Safety Monitoring of Medicinal Products: Reporting Systems For The General Public.
348 2000 [cited 2024 Jan 8];35(3):41–3. Available from:
349 [http://www.scopus.com/inward/record.url?eid=2-s2.0-](http://www.scopus.com/inward/record.url?eid=2-s2.0-0025317538&partnerID=40&md5=6ff30e08e26b99f08c46a3bb4c28a332)
350 [0025317538&partnerID=40&md5=6ff30e08e26b99f08c46a3bb4c28a332](http://www.scopus.com/inward/record.url?eid=2-s2.0-0025317538&partnerID=40&md5=6ff30e08e26b99f08c46a3bb4c28a332)
- 351 7. Our World in Data. Total number of people who received at least one dose of COVID-19
352 vaccine [Internet]. Our World in Data. 2023 [cited 2024 Jan 8]. Available from:
353 <https://ourworldindata.org/grapher/people-vaccinated-covid>
- 354 8. Laczkó D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, et al. A Single
355 Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and
356 Humoral Immune Responses against SARS-CoV-2 in Mice. *Immunity* [Internet]. 2020 Oct
357 10 [cited 2024 Jan 8];53(4):724. Available from: [/pmc/articles/PMC7392193/](https://pubmed.ncbi.nlm.nih.gov/35146337/)
- 358 9. Vanaparthi R, Mohan G, Vasireddy D, Atluri P. Review of COVID-19 viral vector-based
359 vaccines and COVID-19 variants. *Le Infez Med* [Internet]. 2021 [cited 2024 Jan
360 8];29(3):328–38. Available from: <https://pubmed.ncbi.nlm.nih.gov/35146337/>
- 361 10. Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse Events Reported
362 From COVID-19 Vaccine Trials: A Systematic Review. *Indian J Clin Biochem* [Internet]. 2021
363 Oct 1 [cited 2024 Jan 8];36(4):427. Available from: [/pmc/articles/PMC7997788/](https://pubmed.ncbi.nlm.nih.gov/35146337/)
- 364 11. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy
365 of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* [Internet]. 2020 Dec 31 [cited 2024
366 Jan 8];383(27):2603–15. Available from: <https://pubmed.ncbi.nlm.nih.gov/33301246/>

- 367 12. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and
368 SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the
369 UK: a prospective observational study. *Lancet Infect Dis* [Internet]. 2021 Jul 1 [cited 2024
370 Jan 8];21(7):939–49. Available from: <https://pubmed.ncbi.nlm.nih.gov/33930320/>
- 371 13. Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Analysis of COVID-19
372 Vaccine Type and Adverse Effects Following Vaccination. *JAMA Netw open* [Internet]. 2021
373 Dec 22 [cited 2024 Jan 9];4(12). Available from:
374 <https://pubmed.ncbi.nlm.nih.gov/34935921/>
- 375 14. Boi-Dsane NAA, Dzudzor B, Alhassan Y, Aheto JMK. Prevalence of common adverse events
376 experienced following COVID-19 vaccination and its associated factors in Ghana: Cross-
377 sectional study design. *Heal Sci reports* [Internet]. 2022 Jan 1 [cited 2024 Jan 9];6(1).
378 Available from: <https://pubmed.ncbi.nlm.nih.gov/36582625/>
- 379 15. Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, et al.
380 Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of
381 Randomized Clinical Trials. *Vaccines* [Internet]. 2021 May 1 [cited 2024 Jan 9];9(5).
382 Available from: <https://pubmed.ncbi.nlm.nih.gov/34066475/>
- 383 16. Jarso G, Gebi W, Abdo M, Lemma M, Abebe E, Lemessa B, et al. Prevalence of COVID-19
384 Vaccine Side Effects among Early-Vaccinated Healthcare Workers in Eastern Ethiopia.
385 *Ethiop J Health Sci* [Internet]. 2022 May 1 [cited 2024 Jan 9];32(3):473. Available from:
386 </pmc/articles/PMC9214739/>
- 387 17. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy

- 388 of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* [Internet]. 2020 Dec 31 [cited 2024
389 Jan 9];383(27):2603–15. Available from: <https://pubmed.ncbi.nlm.nih.gov/33301246/>
- 390 18. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the
391 mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* [Internet]. 2021 Feb 4 [cited 2024 Jan
392 9];384(5):403–16. Available from: <https://pubmed.ncbi.nlm.nih.gov/33378609/>
- 393 19. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the
394 BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. *N Engl J Med* [Internet]. 2021
395 Sep 16 [cited 2024 Jan 9];385(12):1078–90. Available from:
396 <https://pubmed.ncbi.nlm.nih.gov/34432976/>
- 397 20. Chen G, Li X, Sun M, Zhou Y, Yin M, Zhao B, et al. COVID-19 mRNA Vaccines Are Generally
398 Safe in the Short Term: A Vaccine Vigilance Real-World Study Says. *Front Immunol*. 2021
399 May 21;12:669010.
- 400 21. Kitagawa H, Kaiki Y, Sugiyama A, Nagashima S, Kurisu A, Nomura T, et al. Adverse reactions
401 to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan. *J Infect Chemother*
402 [Internet]. 2022 Apr 1 [cited 2024 Jan 9];28(4):576–81. Available from:
403 <https://pubmed.ncbi.nlm.nih.gov/35058126/>
- 404 22. Valera-Rubio M, Sierra-Torres MI, Castillejo García R, Cordero-Ramos J, López-Márquez
405 MR, Cruz-Salgado Ó, et al. Adverse events reported after administration of BNT162b2 and
406 mRNA-1273 COVID-19 vaccines among hospital workers: a cross-sectional survey-based
407 study in a Spanish hospital. *Expert Rev Vaccines* [Internet]. 2022 [cited 2024 Jan 9];21(4):1.
408 Available from: [/pmc/articles/PMC8787836/](https://pubmed.ncbi.nlm.nih.gov/35058126/)

- 409 23. Chapin-Bardales J, Gee J, Myers T. Reactogenicity Following Receipt of mRNA-Based
410 COVID-19 Vaccines. JAMA [Internet]. 2021 Jun 1 [cited 2024 Jan 9];325(21):2201–2.
411 Available from: <https://jamanetwork.com/journals/jama/fullarticle/2778441>

412



medRxiv preprint doi: <https://doi.org/10.1101/2024.08.18.24312190>; this version posted August 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 1: Frequency of reported AEFIs